The current study investigated the anti-inflammatory effect of 0.1% tacrolimus eye drops for the treatment of therapeutic penetrating keratoplasty (TPK) for severe infectious keratitis during early disease stages and reported the longterm clinical outcomes. The present retrospective
study included 20 eyes from patients diagnosed with severe keratitis who underwent TPK surgery. Patients were followedup for up to 1218 months. Tacrolimus eye drops were administered 4 times/day starting on the first day postsurgery. Glucocorticoid eye drops were subsequently added
to treatment plans onemonth postsurgery. All patients were followedup for the first 3 postoperative days, then examined once a week thereafter for the first month. In early postoperative stages, the states of the grafts (ΔS) and the absorption of intraocular inflammation (S) were observed.
ΔS was defined as the difference between the states of the grafts on the first postoperative day (SS1d) and those at one month postsurgery (SS1m). S was calculated as the difference between the inflammation score mean one day postsurgery (T1d) and the mean onemonth postsurgery (T1m).
For long term clinical outcomes, graft failure rates and complications were recorded. Among the 20 eyes analyzed, the mean T1d, T1m and S were 7.4±2.06, 2.0±2.47 and 5.4±2.13 (P<0.01), respectively. The mean SS1d, SS1m and ΔS were 5.3±1.56, 3.8±1.24
and 1.5±1.5 (P<0.01), respectively. During followup, there were 6 cases of corneal graft failure, 4 of which were due to immune rejection and 2 of which were due to complications. The current study concluded that tacrolimus eye drops facilitated the absorption of intraocular
inflammation in the early postoperative period of TPK and may extend long term survival of grafts in cases of severe infectious keratitis.
No Reference information available - sign in for access.
No Citation information available - sign in for access.
No Supplementary Data.
No Article Media
Document Type: Research Article
Beijing Tongren Eye Center, Beijing Tongren Hospital, Beijing Institute of Ophthalmology, Capital Medical University, Beijing 100730, P.R. China
Department of Ophthalmology, Beijing You'an Hospital, Capital Medical University, Beijing 100069, P.R. China
October 1, 2020
More about this publication?
Experimental and Therapeutic Medicine aims to ensure the expedient publication, in both print and electronic format, of studies relating to biology, gene therapy, infectious disease, microbiology, molecular cardiology and molecular surgery. The journal welcomes studies pertaining to all aspects of molecular medicine, and studies relating to in vitro or in vivo experimental model systems relevant to the mechanisms of disease are also included.
All materials submitted to this journal undergo the appropriate review via referees who are experts in this field. All materials submitted follow international guidelines with regard to approval of experiments on humans and animals.
- Editorial Board
- Information for Authors
- Submit a Paper
- Subscribe to this Title
- Information for Advertisers
- Terms & Conditions
- Ingenta Connect is not responsible for the content or availability of external websites